Cosmos Health Inc.
COSM Healthcare Medical Distribution
Cosmos Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.3 million, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 28.8%, EPS was flat, free cash flow grew 9.39% and total debt rose 15.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow COSM
Cosmos Health Inc. (COSM) EV/Sales
As of 16 October 2026, Cosmos Health Inc. (COSM) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from −0.1× (March 2023) to 0.9× (July 2023); the current reading is higher than 77% of that period. That is below the Medical Distribution industry median of 0.6× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.4× | 5.66% |
| FY2024 | 0.4× | (7.13%) |
| FY2023 | 0.4× | 21,815.79% |
| FY2022 | 0.0× | (99.54%) |
| FY2021 | 0.4× | 9.10% |
| FY2020 | 0.4× | 139.40% |
| FY2019 | 0.2× | 73.66% |
| FY2018 | 0.1× | (42.13%) |
| FY2017 | 0.2× | (70.09%) |
| FY2016 | 0.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.3× | (27.40%) |
| Mar 2026 | 0.4× | (5.41%) |
| Dec 2025 | 0.4× | (42.68%) |
| Sep 2025 | 0.7× | 81.77% |
| 38 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HKPD Cellyan Biotechnology Co., Ltd compare | n/m |
| YI 111, Inc. Sponsored ADR compare | 0.0× |
| CAH Cardinal Health, Inc. compare | 0.3× |
| COSM Cosmos Health Inc. | 0.4× |
| ACH Accendra Health, Inc. compare | 0.9× |
| HSIC Henry Schein, Inc. compare | 0.9× |
| SNYRQ Synergy CHC Corp. compare | 0.9× |
| AHG Akso Health Group Sponsored ADR compare | 1.8× |
| FOCL FocalTherics compare | 2.1× |
| Medical Distribution industry median | 0.6× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)